SUMEJ
Sumatera Medical Journal
Journal homepage: https://talenta.usu.ac.id/smj

Depression and Type 2 Diabetes: Dissecting the Causal Mechanisms

Awani Kumar Diwakar*[1]
[1]*SRM Institute of Science and Technology, Chennai, 603203, India*
*Corresponding Author: avanikumardivakar@gmail.com

ARTICLE INFO

Article history:
Received 1 April 2024
Revised 28 April 2024
Accepted 1 May 2024
Available online 1 May 2024

E-ISSN: 2622-1357
P-ISSN: 2622-9234

How to cite:
Awani Kumar Diwakar,"Depression and Type 2 Diabetes: Dissecting the Causal Mechanisms" SUMEJ, vol. 07, no. 02, May 2024

ABSTRACT

Depression and Type 2 Diabetes (T2D) are two prevalent and debilitating chronic conditions that often coexist and exhibit a bidirectional relationship. This review paper aims to dissect the causal mechanisms underlying the association between depression and T2D, shedding light on the complex interplay between these two disorders. Epidemiological evidence suggests a robust association between depression and an increased risk of developing T2D, as well as a reciprocal relationship where T2D serves as a risk factor for depression onset. Various biological, psychological, and behavioral mechanisms have been proposed to underlie this bidirectional relationship. Depression is thought to contribute to the development of T2D through dysregulation of neuroendocrine pathways, increased inflammation, alterations in lifestyle behaviors, and poor treatment adherence. Conversely, T2D may exacerbate or precipitate depression through mechanisms involving insulin resistance, hyperglycemia-induced neuronal damage, inflammation, and the impact of chronic illness on psychological well-being. Shared pathophysiological mechanisms between depression and T2D, including dysregulation of the hypothalamic-pituitary-adrenal axis, insulin signaling pathways, and inflammatory processes, further contribute to their co-occurrence. Psychosocial factors such as socioeconomic status, social support, and access to healthcare also play significant roles in shaping the depression-T2D relationship. Integrated care models that address both physical and mental health needs, along with targeted interventions addressing lifestyle modifications and psychosocial support, are essential for managing these comorbid conditions effectively. Future research directions include longitudinal studies to elucidate temporal associations, intervention trials targeting shared mechanisms, and precision medicine approaches to identify subgroups at heightened risk. Understanding the causal mechanisms underlying the depression-T2D relationship is crucial for informing clinical practice, public health strategies, and the development of personalized interventions aimed at mitigating the burden of these interconnected disorders.

Keywords: Depression, Diabetes, Pituitary, Psychological, Neuroendocrine

http://doi.org/10.32734/sumej.v7i2.16112

1. Introduction

Depression and Type 2 Diabetes (T2D) are two prevalent and burdensome chronic health conditions that affect millions of individuals worldwide. Depression, characterized by persistent feelings of sadness, hopelessness, and loss of interest or pleasure in activities, is one of the leading causes of disability globally [1]. According to the World Health Organization (WHO), depression affects over 264 million people of all ages globally, with significant impacts on quality of life, productivity, and overall well-being. Type 2 Diabetes, on the other hand, is a metabolic disorder characterized by elevated blood sugar levels resulting from insulin resistance and inadequate insulin production. It represents a major public health concern, with approximately 463 million adults diagnosed with diabetes worldwide. T2D is associated with a multitude of

complications, including cardiovascular disease, neuropathy, retinopathy, and kidney disease, leading to increased morbidity and mortality rates [2]. While depression and T2D are distinct clinical entities, emerging evidence suggests a bidirectional relationship between these two conditions. Epidemiological studies have consistently demonstrated that individuals with depression are at an increased risk of developing T2D, and conversely, individuals with T2D have a higher prevalence of depression compared to the general population [3]. This bidirectional relationship has significant implications for the management and outcomes of both conditions, highlighting the need for a deeper understanding of the underlying causal mechanisms.

Significance of Understanding Causal Mechanisms

Understanding the causal mechanisms linking depression and T2D is of paramount importance for several reasons. Firstly, elucidating these mechanisms can provide insights into the shared biological pathways and risk factors that contribute to the development and progression of both conditions. By identifying common etiological factors, such as chronic inflammation, neuroendocrine dysregulation, and genetic predispositions, researchers and clinicians can better understand the complex interplay between depression and T2D and develop targeted interventions aimed at addressing underlying pathophysiological processes [4].

Secondly, understanding the causal mechanisms underlying the depression-T2D relationship can inform clinical practice and improve patient care. Healthcare providers can use this knowledge to identify individuals at heightened risk of developing T2D or depression and implement preventive measures, such as lifestyle modifications, early screening, and psychosocial support interventions. Moreover, clinicians can tailor treatment approaches to address the unique needs and challenges faced by patients with comorbid depression and T2D, thereby optimizing health outcomes and reducing the burden of both conditions.

Thirdly, unraveling the causal mechanisms linking depression and T2D has significant implications for public health policy and healthcare delivery [5]. By recognizing the bidirectional nature of the association and the multifaceted pathways involved, policymakers and healthcare stakeholders can develop holistic approaches to disease prevention and management that address both physical and mental health needs. Integrated care models that incorporate mental health screening, diabetes management, and behavioral interventions can help bridge the gap between mental health and primary care services, improving access to comprehensive care for individuals with comorbid depression and T2D.

Understanding the causal mechanisms underlying the bidirectional relationship between depression and Type 2 Diabetes is crucial for advancing research, informing clinical practice, and guiding public health interventions aimed at addressing these interconnected health challenges [6]. By elucidating the shared biological pathways, risk factors, and psychosocial determinants involved, researchers and clinicians can develop targeted interventions that promote holistic health and well-being for individuals affected by depression and T2D.

Epidemiological Evidence of the Relationship Between Depression and Type 2 Diabetes

Depression and Type 2 Diabetes (T2D) are two common chronic health conditions that often coexist and exhibit a bidirectional relationship. Epidemiological studies have provided valuable insights into the nature of this relationship, highlighting the prevalence, incidence, and risk factors associated with comorbid depression and T2D.

Overview of Epidemiological Studies

Numerous epidemiological studies conducted over the past few decades have consistently demonstrated a significant association between depression and T2D [7]. These studies have employed various study designs, including cross-sectional, longitudinal, and case-control designs, to investigate the prevalence, incidence, and risk factors of comorbid depression and T2D in diverse populations. Cross-sectional studies have provided valuable information on the prevalence of depression among individuals with T2D and vice versa. These studies typically involve the assessment of depression and T2D status at a single time point, allowing researchers to estimate the prevalence of comorbid conditions within a population. Longitudinal studies, on the other hand, have examined the temporal relationship between depression and T2D, assessing the risk of developing one condition following the onset of the other over time. By following individuals longitudinally, researchers can determine whether depression precedes the development of T2D, or vice versa, and identify potential risk factors and mechanisms underlying the association [5-6].

Prevalence and Incidence Rates

The prevalence of comorbid depression and T2D varies across different populations and settings, but epidemiological studies consistently report higher rates of depression among individuals with T2D compared to the general population. Similarly, individuals with depression are at an increased risk of developing T2D

compared to those without depression. A meta-analysis conducted by Knol et al. (2006) found that individuals with depression had a 60% increased risk of developing T2D compared to non-depressed individuals, even after adjusting for potential confounding factors such as age, sex, and body mass index [8]. The prevalence of depression among individuals with T2D has been estimated to be approximately two to three times higher than that of the general population, with rates ranging from 15% to 30% in various studies. Conversely, the prevalence of T2D among individuals with depression is also elevated, with estimates suggesting that up to 20% of individuals with depression may have comorbid T2D. These findings highlight the substantial burden of comorbid depression and T2D on public health and underscore the importance of early detection and intervention to mitigate adverse outcomes [8].

Risk Factors and Associations

Epidemiological studies have identified several risk factors and associations that contribute to the relationship between depression and T2D. Common risk factors for both conditions include obesity, physical inactivity, poor diet, smoking, and socioeconomic disadvantage [9]. Psychosocial factors such as chronic stress, social isolation, and adverse life events have also been implicated in the development of both depression and T2D. Furthermore, certain demographic factors, such as age, sex, and ethnicity, may influence the risk of developing comorbid depression and T2D.

For example, older adults, women, and individuals from minority ethnic groups may be at a higher risk of experiencing both depression and T2D compared to younger adults, men, and individuals from non-minority ethnic groups. In addition to these demographic and lifestyle factors, biological mechanisms such as inflammation, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, and alterations in neurotransmitter systems have been proposed to underlie the association between depression and T2D. Chronic inflammation, in particular, has emerged as a key mediator of the bidirectional relationship, contributing to insulin resistance, beta-cell dysfunction, and impaired glucose metabolism in individuals with depression and T2D.

Overall, epidemiological evidence suggests a complex and multifactorial relationship between depression and Type 2 Diabetes, with shared risk factors, biological mechanisms, and psychosocial determinants contributing to the co-occurrence of these two conditions [10]. Understanding the epidemiological evidence underlying this relationship is essential for informing preventive strategies, early detection efforts, and targeted interventions aimed at reducing the burden of comorbid depression and T2D on individuals and healthcare systems.

Bidirectional Relationship: Depression as a Risk Factor for Type 2 Diabetes

Depression and Type 2 Diabetes (T2D) are two chronic health conditions that often coexist and exhibit a bidirectional relationship. While the association between depression and T2D has been well-established, emerging evidence suggests that depression may also serve as a risk factor for the development and progression of T2D. This bidirectional relationship has significant implications for the management and outcomes of both conditions, highlighting the importance of understanding the underlying mechanisms and risk factors involved [11].

Depression, characterized by persistent feelings of sadness, hopelessness, and loss of interest or pleasure in activities, has been identified as a potential risk factor for the development of T2D. Epidemiological studies have consistently demonstrated a higher prevalence of T2D among individuals with depression compared to the general population. Furthermore, longitudinal studies have shown that individuals with depression are at an increased risk of developing T2D over time, even after adjusting for potential confounding factors such as age, sex, and body mass index. Several mechanisms have been proposed to explain the association between depression and T2D, including biological, psychological, and behavioral pathways.

Chronic activation of the stress response system, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, and alterations in neurotransmitter systems have been implicated in the development of both depression and T2D [12]. For example, chronic stress and elevated levels of cortisol, the primary stress hormone, can lead to insulin resistance, impaired glucose metabolism, and dysregulation of appetite and energy balance, predisposing individuals to T2D. In addition to biological mechanisms, psychological and behavioral factors associated with depression may also contribute to the development of T2D.

Individuals with depression often engage in maladaptive coping behaviors such as unhealthy eating habits, sedentary lifestyle, and poor medication adherence, all of which are known risk factors for T2D. Moreover, depression is associated with alterations in sleep patterns, circadian rhythms, and social functioning, which may further exacerbate metabolic dysregulation and increase the risk of T2D. Furthermore, socioeconomic

disadvantage, social isolation, and adverse life events commonly experienced by individuals with depression may contribute to the development of T2D through pathways involving chronic stress, unhealthy coping mechanisms, and limited access to resources for managing chronic health conditions [13]. For example, individuals with depression may have limited access to healthy food options, healthcare services, and social support networks, which can exacerbate their risk of developing T2D and hinder their ability to effectively manage their diabetes.

Overall, depression appears to serve as a significant risk factor for the development and progression of Type 2 Diabetes. Understanding the bidirectional relationship between depression and T2D is essential for informing preventive strategies, early detection efforts, and targeted interventions aimed at reducing the burden of both conditions on individuals and healthcare systems. By addressing the underlying mechanisms and risk factors involved, clinicians and public health practitioners can develop holistic approaches to disease prevention and management that address both physical and mental health needs. In addition to the biological, psychological, and behavioral mechanisms discussed earlier, several other factors may contribute to depression serving as a risk factor for Type 2 Diabetes [12].

a. Inflammation: Depression is associated with chronic low-grade inflammation, characterized by elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). This inflammatory state has been linked to insulin resistance and impaired glucose metabolism, increasing the risk of developing Type 2 Diabetes. Moreover, inflammatory processes in depression may exacerbate existing metabolic abnormalities, further predisposing individuals to T2D [11].

b. Dysregulation of Neuroendocrine Axis: Depression is characterized by dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in abnormal cortisol secretion patterns and heightened stress responses. Chronic activation of the HPA axis and prolonged exposure to elevated cortisol levels can lead to insulin resistance and beta-cell dysfunction, contributing to the pathogenesis of T2D [10]. Additionally, alterations in other neuroendocrine pathways, such as the sympathetic nervous system and the hypothalamic-pituitary-thyroid axis, may also play a role in linking depression to T2D risk.

c. Genetic and Epigenetic Factors: Genetic predisposition and epigenetic modifications may contribute to the bidirectional relationship between depression and T2D. Shared genetic susceptibility loci have been identified for both conditions, including genes involved in neurotransmitter signaling, stress response pathways, and immune function. Epigenetic modifications, such as DNA methylation and histone acetylation, can influence gene expression patterns and contribute to the development of both depression and T2D [11-12]. Understanding the interplay between genetic and environmental factors in shaping the risk of comorbid depression and T2D is an area of active research.

d. Medication Effects: Certain medications used in the treatment of depression, such as selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, and corticosteroids, may adversely affect glucose metabolism and increase the risk of insulin resistance and T2D. These medications can lead to weight gain, dyslipidemia, and alterations in insulin sensitivity, thereby exacerbating existing metabolic abnormalities or predisposing individuals to develop T2D. Clinicians should carefully monitor metabolic parameters in patients receiving psychotropic medications, particularly those at high risk of developing T2D [13].

e. Shared Lifestyle Factors: Individuals with depression often exhibit unhealthy lifestyle behaviors, including poor dietary choices, physical inactivity, smoking, and excessive alcohol consumption, which are known risk factors for T2D. These lifestyle factors may contribute to weight gain, visceral adiposity, and metabolic dysfunction, increasing the risk of developing insulin resistance and T2D. Moreover, depression-related alterations in appetite, cravings, and hedonic responses to food may promote the consumption of high-calorie, nutrient-poor foods, further exacerbating metabolic abnormalities.

In summary, depression serves as a multifaceted risk factor for the development and progression of Type 2 Diabetes, involving complex interactions between biological, psychological, behavioral, and environmental factors. Understanding the diverse mechanisms linking depression to T2D risk is essential for identifying individuals at heightened risk, implementing preventive interventions, and optimizing treatment strategies for both conditions. By addressing the underlying contributors to the bidirectional relationship, clinicians and public health practitioners can develop comprehensive approaches to disease prevention and management that address the complex interplay between mental and physical health.

Shared Pathophysiological Mechanisms Between Depression and Type 2 Diabetes

Depression and Type 2 Diabetes (T2D) are complex and multifaceted conditions with overlapping pathophysiological mechanisms. Understanding the shared biological pathways underlying these two disorders is crucial for elucidating their bidirectional relationship and developing targeted interventions for

individuals affected by comorbid depression and T2D [14]. This article provides an overview of the key shared biological pathways, including inflammation and oxidative stress, insulin resistance and glucose dysregulation, and neuroendocrine dysfunction, linking depression and T2D.

Overview of Shared Biological Pathways

Both depression and T2D are characterized by disturbances in various biological systems, including the immune, endocrine, and nervous systems. Shared biological pathways between depression and T2D involve complex interactions between genetic, environmental, and lifestyle factors, contributing to the development and progression of both conditions [14]. These shared pathways encompass alterations in inflammatory processes, oxidative stress, insulin signaling, glucose metabolism, and neuroendocrine regulation, among others.

a. Role of Inflammation and Oxidative Stress

Chronic low-grade inflammation and oxidative stress are integral components of the pathophysiology of both depression and Type 2 Diabetes. In depression, increased levels of pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) have been observed in the peripheral blood, cerebrospinal fluid, and brain regions implicated in mood regulation. These inflammatory processes can disrupt neurotransmitter metabolism, synaptic plasticity, and neurogenesis, contributing to the development and persistence of depressive symptoms. Similarly, in Type 2 Diabetes, chronic systemic inflammation is characterized by elevated levels of circulating inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and TNF-alpha [15]. Adipose tissue dysfunction, ectopic lipid accumulation, and activation of inflammatory pathways, such as nuclear factor-kappa B (NF-kB) signaling, contribute to the release of pro-inflammatory cytokines and chemokines. This chronic inflammatory state impairs insulin signaling, promotes insulin resistance, and contributes to the development of beta-cell dysfunction and pancreatic inflammation, ultimately exacerbating glucose dysregulation in T2D. Oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, is also implicated in both depression and Type 2 Diabetes. Oxidative stress can lead to cellular damage, mitochondrial dysfunction, and impaired antioxidant capacity, contributing to neurodegeneration, beta-cell dysfunction, and endothelial dysfunction in T2D. In depression, oxidative stress can disrupt neuronal function, promote neuronal apoptosis, and exacerbate neuroinflammation, further perpetuating depressive symptoms.

b. Implications of Insulin Resistance and Glucose Dysregulation

Insulin resistance, a central feature of Type 2 Diabetes, occurs when target tissues such as skeletal muscle, liver, and adipose tissue become less responsive to insulin signaling, leading to impaired glucose uptake and utilization. Insulin resistance is associated with dyslipidemia, endothelial dysfunction, and systemic inflammation, all of which contribute to the pathogenesis of T2D [16]. In depression, insulin resistance and impaired glucose metabolism have also been observed, independent of T2D diagnosis. Studies have shown that individuals with depression exhibit insulin resistance, impaired glucose tolerance, and dysregulated glycemic control, even in the absence of obesity or metabolic syndrome. Insulin resistance in depression may be mediated by neuroendocrine dysregulation, chronic stress, and alterations in neurotransmitter systems, such as serotonin and dopamine, which influence insulin sensitivity and glucose homeostasis. Glucose dysregulation in depression may exacerbate depressive symptoms and increase the risk of developing T2D. Hyperglycemia, glucose variability, and fluctuations in insulin levels can impair neuronal function, disrupt neurotransmitter balance, and exacerbate mood disturbances in individuals with depression. Conversely, insulin resistance and dysregulated glucose metabolism in T2D can contribute to neuronal damage, neuroinflammation, and alterations in neurotrophic factors, which may increase susceptibility to depression.

c. Impact of Neuroendocrine Dysfunction

Neuroendocrine dysregulation, involving alterations in the hypothalamic-pituitary-adrenal (HPA) axis, sympathetic nervous system (SNS), and other hormonal systems, is implicated in both depression and Type 2 Diabetes [15]. Dysregulation of the HPA axis, characterized by hyperactivity of the adrenal cortex and dysregulated cortisol secretion, is a common feature of depression and is associated with depressive symptoms, cognitive deficits, and alterations in mood regulation. Similarly, dysregulated cortisol secretion and abnormalities in glucocorticoid receptor signaling have been implicated in the pathophysiology of Type 2 Diabetes, contributing to insulin resistance, adiposity, and metabolic dysfunction. Furthermore, alterations in sympathetic nervous system activity, including increased sympathetic tone and catecholamine release, may contribute to both depression and Type 2 Diabetes by promoting insulin resistance, dyslipidemia, and cardiovascular dysfunction [16]. Overall, shared pathophysiological mechanisms between depression and Type 2 Diabetes involve complex interactions between inflammation, oxidative stress, insulin resistance, glucose dysregulation, and neuroendocrine dysfunction. These shared pathways contribute to the bidirectional relationship between depression and Type 2 Diabetes, underscoring the importance of addressing both mental and physical health needs in affected individuals. Targeted interventions aimed at

modulating these shared biological pathways may offer new avenues for the prevention and treatment of both conditions, ultimately improving health outcomes and quality of life for affected individuals.

In summary, depression and Type 2 Diabetes share several pathophysiological mechanisms, including inflammation and oxidative stress, insulin resistance and glucose dysregulation, and neuroendocrine dysfunction. These shared pathways contribute to the bidirectional relationship between depression and T2D and underscore the importance of addressing both mental and physical health needs in individuals affected by comorbid depression and T2D. Targeted interventions aimed at modulating these shared biological pathways may offer new avenues for the prevention and treatment of both conditions, ultimately improving health outcomes and quality of life for affected individuals.

Implications for Clinical Practice and Public Health

Depression and Type 2 Diabetes (T2D) represent significant public health challenges, with profound implications for individual health outcomes, healthcare utilization, and healthcare costs. The bidirectional relationship between depression and T2D underscores the importance of integrated approaches to disease management and prevention, addressing both mental and physical health needs [10]. This article explores the implications of the depression-T2D relationship for clinical practice and public health, focusing on screening and detection strategies, integrated care models, and targeted interventions and prevention efforts.

a. *Screening and Detection Strategies:* Given the high prevalence and adverse impact of comorbid depression and T2D, routine screening and detection of both conditions are essential components of comprehensive healthcare delivery. Screening tools such as the Patient Health Questionnaire-9 (PHQ-9) for depression and the American Diabetes Association (ADA) risk assessment tool for T2D can help identify individuals at risk and facilitate early intervention [17]. Primary care providers play a crucial role in implementing screening protocols, conducting regular assessments, and monitoring patients for signs and symptoms of depression and T2D. Integration of mental health screening into routine diabetes care and vice versa can enhance detection rates and improve outcomes for individuals with comorbid depression and T2D. Collaborative care models that involve multidisciplinary teams, including primary care physicians, mental health professionals, diabetes educators, and other healthcare providers, can facilitate coordinated screening, assessment, and management of both conditions. Electronic health record (EHR) systems and decision support tools can streamline screening processes, prompt providers to administer standardized assessments, and facilitate communication and referrals between healthcare providers.

b. *Integrated Care Models:* Integrated care models that address both mental and physical health needs are essential for optimizing outcomes in individuals with comorbid depression and T2D. Collaborative care models, such as the Collaborative Care for Depression and Chronic Illness (CCDCI) model, have demonstrated efficacy in improving clinical outcomes, enhancing patient satisfaction, and reducing healthcare costs in individuals with comorbid depression and chronic medical conditions, including T2D. These integrated care models typically involve a team-based approach to healthcare delivery, incorporating elements such as care coordination, case management, psychoeducation, pharmacotherapy, and psychotherapy [18]. Primary care providers serve as the central point of contact, coordinating care and collaborating with specialty mental health providers, diabetes educators, and other healthcare professionals to address the diverse needs of individuals with comorbid depression and T2D. Telehealth and digital health technologies can further facilitate access to integrated care services, particularly in underserved or remote communities.

c. *Targeted Interventions and Prevention Efforts:* Targeted interventions aimed at addressing modifiable risk factors and underlying mechanisms of the depression-T2D relationship can help prevent the onset and progression of both conditions. Lifestyle interventions focusing on diet, physical activity, and weight management are essential components of T2D prevention and management and may also have beneficial effects on mood and mental health [17]. Behavioral interventions such as cognitive-behavioral therapy (CBT) and mindfulness-based interventions can help individuals with depression develop coping skills, improve self-care behaviors, and enhance resilience in the face of chronic illness. Moreover, pharmacological interventions targeting shared pathophysiological mechanisms between depression and T2D, such as inflammation, oxidative stress, and neuroendocrine dysregulation, hold promise for improving outcomes in individuals with comorbid depression and T2D. For example, medications with dual effects on mood and metabolism, such as certain antidepressants and antidiabetic agents, may provide synergistic benefits in individuals with comorbid depression and T2D. However, careful consideration of potential side effects, drug interactions, and individual preferences is essential when selecting pharmacological treatments [18]. Prevention efforts aimed at reducing the incidence and prevalence of both depression and T2D at the population level are also critical for addressing the burden of these conditions on public health. Public health initiatives promoting healthy lifestyle behaviors, early intervention, and access to integrated care services can help reduce the risk of developing both depression and T2D and improve overall population

health outcomes. Community-based programs, workplace wellness initiatives, and school-based interventions can empower individuals and communities to make informed choices about their health and well-being, ultimately reducing the societal burden of comorbid depression and T2D.

In summary, the bidirectional relationship between depression and Type 2 Diabetes has significant implications for clinical practice and public health. Screening and detection strategies, integrated care models, and targeted interventions and prevention efforts are essential components of comprehensive healthcare delivery for individuals with comorbid depression and T2D. By addressing both mental and physical health needs and targeting shared pathophysiological mechanisms, healthcare providers and public health practitioners can improve outcomes and quality of life for affected individuals and reduce the societal burden of comorbid depression and T2D.

[A] Clinical Practice:

a. Tailored Treatment Plans: Healthcare providers should develop tailored treatment plans for individuals with comorbid depression and T2D, taking into account the unique needs, preferences, and goals of each patient. Treatment plans may include a combination of pharmacotherapy, psychotherapy, lifestyle interventions, and self-management strategies to address both mental and physical health concerns [9].

b. Regular Monitoring and Follow-Up: Regular monitoring and follow-up are essential components of clinical care for individuals with comorbid depression and T2D. Healthcare providers should conduct regular assessments of depressive symptoms, glycemic control, medication adherence, and diabetes-related complications to ensure optimal management of both conditions. Telehealth and remote monitoring technologies can facilitate ongoing communication and support between patients and healthcare providers, particularly for individuals with limited access to in-person care [13].

c. Patient Education and Empowerment: Patient education and empowerment are critical for promoting self-management skills and improving health outcomes in individuals with comorbid depression and T2D. Healthcare providers should provide comprehensive education on the link between depression and T2D, the importance of medication adherence, blood glucose monitoring, healthy lifestyle behaviors, and stress management techniques. Empowering patients to take an active role in their care can enhance treatment adherence, improve self-efficacy, and promote better outcomes [12].

d. Culturally Competent Care: Culturally competent care is essential for addressing the diverse needs and preferences of individuals with comorbid depression and T2D from different cultural backgrounds. Healthcare providers should be sensitive to cultural beliefs, values, and practices related to mental health, diabetes management, and healthcare-seeking behavior. Culturally tailored interventions and language-appropriate materials can improve communication, trust, and engagement with healthcare services among culturally diverse populations.

[B] Public Health:

a. Health Promotion and Prevention: Public health initiatives aimed at promoting mental and physical well-being can help prevent the onset and progression of both depression and T2D at the population level [17]. Health promotion campaigns focusing on healthy lifestyle behaviors, early intervention, and access to integrated care services can raise awareness, reduce stigma, and empower individuals to make positive choices about their health. Community-based programs, workplace wellness initiatives, and school-based interventions can promote health literacy, foster supportive environments, and encourage healthy behaviors among individuals and families.

b. Policy Advocacy and Systems Change: Policy advocacy and systems change are essential for creating environments that support mental and physical health across the lifespan. Public health practitioners, policymakers, and healthcare stakeholders should advocate for policies and programs that promote mental health parity, improve access to integrated care services, and address social determinants of health such as poverty, housing instability, and food insecurity [18]. Additionally, investments in healthcare infrastructure, workforce development, and technology-enabled care delivery can strengthen healthcare systems and improve health outcomes for individuals with comorbid depression and T2D.

c. Data Surveillance and Research: Data surveillance and research are critical for monitoring trends, identifying disparities, and informing evidence-based interventions to address the burden of comorbid depression and T2D. Public health agencies should collect and analyze data on the prevalence, incidence, and impact of both conditions, as well as their risk factors and determinants [18]. Epidemiological studies, health services research, and implementation science can provide insights into effective strategies for preventing, diagnosing, and managing comorbid depression and T2D in diverse populations.

d. Partnerships and Collaboration: Partnerships and collaboration among healthcare providers, community organizations, advocacy groups, and policymakers are essential for addressing the complex challenges associated with comorbid depression and T2D. Multi-sectoral collaborations can leverage resources, expertise, and networks to develop innovative solutions, scale evidence-based interventions, and advocate for policy changes that promote mental and physical health equity. By working together, stakeholders can create a supportive ecosystem that fosters resilience, reduces disparities, and improves outcomes for individuals with comorbid depression and T2D.

In conclusion, addressing the bidirectional relationship between depression and Type 2 Diabetes requires a multifaceted approach that encompasses clinical practice, public health, policy, and advocacy. By integrating mental and physical health care, promoting prevention and early intervention, advocating for policy changes, and fostering partnerships and collaboration, healthcare providers and public health practitioners can improve outcomes and quality of life for individuals with comorbid depression and T2D, ultimately reducing the societal burden of these interconnected conditions.

2. Conclusion

In conclusion, the bidirectional relationship between depression and Type 2 Diabetes (T2D) represents a complex interplay of biological, psychological, social, and environmental factors that significantly impact individual health outcomes and public health. Through the exploration of shared pathophysiological mechanisms, implications for clinical practice and public health, and strategies for screening, detection, and intervention, this paper has shed light on the multifaceted nature of the depression-T2D relationship and highlighted the importance of integrated approaches to disease management and prevention. The shared biological pathways between depression and T2D, including inflammation, oxidative stress, insulin resistance, glucose dysregulation, and neuroendocrine dysfunction, underscore the interconnectedness of mental and physical health and provide insights into potential targets for intervention. By addressing these shared mechanisms, healthcare providers and public health practitioners can develop targeted interventions aimed at improving outcomes in individuals with comorbid depression and T2D.

In clinical practice, the implementation of screening and detection strategies, integrated care models, and tailored treatment plans is essential for addressing the complex needs of individuals with comorbid depression and T2D. Routine screening for both conditions, along with regular monitoring and follow-up, can facilitate early intervention and prevent adverse outcomes. Integrated care models that involve multidisciplinary teams and collaborative approaches to healthcare delivery can improve coordination, communication, and continuity of care, ultimately enhancing patient outcomes and satisfaction. Moreover, targeted interventions and prevention efforts aimed at modifiable risk factors and shared biological pathways hold promise for reducing the incidence and prevalence of both depression and T2D.

Lifestyle interventions focusing on diet, physical activity, and stress management can improve metabolic health and reduce the risk of developing T2D and depression. Pharmacological interventions targeting inflammation, oxidative stress, and neuroendocrine dysregulation may offer additional benefits in individuals with comorbid depression and T2D. At the population level, public health initiatives aimed at health promotion, prevention, and policy advocacy are essential for addressing the societal burden of comorbid depression and T2D. By raising awareness, reducing stigma, and promoting supportive environments, public health campaigns can empower individuals and communities to make positive choices about their health and well-being. Policy changes that improve access to integrated care services, address social determinants of health, and promote mental health parity can create a more equitable healthcare system that supports the needs of individuals with comorbid depression and T2D.

In conclusion, addressing the bidirectional relationship between depression and Type 2 Diabetes requires a comprehensive and coordinated approach that encompasses clinical practice, public health, policy, and advocacy. By integrating mental and physical health care, promoting prevention and early intervention, advocating for policy changes, and fostering partnerships and collaboration, stakeholders can improve outcomes and quality of life for individuals with comorbid depression and T2D, ultimately reducing the societal burden of these interconnected conditions. Moving forward, continued research, innovation, and collaboration will be essential for advancing our understanding of the depression-T2D relationship and developing effective strategies for prevention, diagnosis, and management.

Ethics approval: Sumatera Medical Journal (SUMEJ) is a peer-reviewed electronic internationaljournal. This statement below clarifies ethical behavior of all parties involved in the act of publishing an article in Sumatera Medical Journal (SUMEJ), including the authors, the chief editor, the Editorial Board, the peer-reviewer and the publisher (TALENTA Publisher Universitas Sumatera Utara). This statement is based on

COPE's Best Practice Guidelines for Journal Editors.

Authors contributions: All authors contributed to the design and implementation of the research, data analysis, and finalizing the manuscript.

Funding: No funding.

Disclosure: Authors declares no conflict of interest.

References

[1] P.K. Prabhakar, K. Singh, D. Kabra, & J. Gupta. "Natural SIRT1 modifiers as promising therapeutic agents for improving diabetic wound healing," *Phytomedicine*, vol. 76, 153252, 2020.

[2] P.K. Prabhakar, D. Nath, S. Singh, A. Mittal, & D.S. Baghel. "Formulation and evaluation of polyherbal anti-acne combination by using in-vitro model," *Biointerface Res. Appl. Chem*, vol. 10, no. 1, pp. 4747-4751, 2020.

[3] R.S. Bergmans, A. Rapp, K.M. Kelly, D. Weiss, & B. Mezuk. "Understanding the relationship between type 2 diabetes and depression: lessons from genetically informative study designs," *Diabetic Medicine*, vol. 38, no. 2, pp. e14399, 2021.

[4] J. M. Zanoveli, H. de Morais, I.C. da Silva Dias, A.K. Schreiber, C.P. de Souza & J.M. da Cunha. "Depression associated with diabetes: from pathophysiology to treatment," *Current diabetes reviews*, vol. 12, no. 3, pp. 165-178, 2016.

[5] W. Katon, M. Maj & N. Sartorius (Eds.). "Depression and diabetes," *John Wiley & Sons*, 2011.

[6] R.I. Holt, M. De Groot, I. Lucki, C.M. Hunter, N. Sartorius, & S.H. Golden. "NIDDK international conference report on diabetes and depression: current understanding and future directions," *Diabetes care*, vol. 37, no. 8, pp. 2067-2077, 2014.

[7] T. Roy, & C.E. Lloyd. "Epidemiology of depression and diabetes: a systematic review," *Journal of affective disorders*, vol. 142, pp. S8-S21, 2012.

[8] K. Ismail, A. Barthel, S.R. Bornstein, & J. Licinio (Eds.). "Depression and type 2 diabetes," *Oxford University Press*, 2018.

[9] A.G. Tabák, T.N. Akbaraly, G.D. Batty, & M. Kivimäki. "Depression and type 2 diabetes: a causal association," *The lancet Diabetes & endocrinology*, vol. 2, no. 3, pp. 236-245, 2014.

[10] C. Tsigos, & G.P. Chrousos. "Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress," *Journal of psychosomatic research*, vol. 53, no. 4, pp. 865-871, 2002.

[11] P.C. Chen, Y.T. Chan, H.F. Chen, M.C. Ko, & C.Y. Li. "Population-based cohort analyses of the bidirectional relationship between type 2 diabetes and depression," *Diabetes care*, vol. 36, no. 2, pp. 376-382, 2013.

[12] B.N. Renn, L. Feliciano, & D.L. Segal. "The bidirectional relationship of depression and diabetes: a systematic review," *Clinical psychology review*, vol. 31, no. 8, pp. 1239-1246, 2011.

[13] A.G. Tabák, T.N. Akbaraly, G.D. Batty, & M. Kivimäki. "Depression and type 2 diabetes: a causal association," *The lancet Diabetes & endocrinology*, vol. 2, no. 3, pp. 236-245, 2014.

[14] D. Liu, R.S. McIntyre, R. Li, M. Yang, Y. Xue, & B. Cao. "Genetic association between major depressive disorder and type 2 diabetes mellitus: Shared pathways and protein networks," *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 111, 110339, 2021.

[15] M.J. Stuart, & B.T. Baune. "Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity," *Neuroscience & Biobehavioral Reviews*, vol. 36, no. 1, pp. 658-676, 2012.

[16] G.Z. Reus, M.A.B. Dos Santos, A.P. Strassi, H.M. Abelaira, L.B. Ceretta, & J. Quevedo. "Pathophysiological mechanisms involved in the relationship between diabetes and major depressive disorder," *Life sciences*, vol. 183, pp. 78-82, 2017.

[17] A. Vassilopoulos, M. Nicholl, R.M. Wolf, K.J. Slifer, & L. Cirincione. "Discrepancies in assessing symptoms of depression in adolescents with diabetes using the patient health questionnaire and semi-structured interviews," *Diabetes Spectrum*, vol. 33, no. 4, pp. 339-346.

[18] J.M. Kretschmar, D.J. Flannery, K. Tossone, M.C. Gearhart, & V. Prevention. "The Cuyahoga County Defending Childhood Initiative: An outcome evaluation," *Begun Center for Violence Prevention Research and Education*, 2016. [Online] Available: https://case.edu/socialwork/begun/sites/case.edu.begun/files/2018-09/DCI-2016-Evaluation.pdf.